Crown Bioscience, a Santa Clara, Calif.-based global drug discovery and development services company, now provides a comprehensive immuno-oncology translational research platform.
“Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer immunotherapies and move the best candidates forward to clinical trials,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.
Crown’s in vitro immuno-oncology assays, including immunophenotyping and immuno-functional assays, help scientists validate immuno-oncology targets, screen for immuno-modulating agents, understand mechanisms of actions and identify biomarkers. With one of the world’s largest collections of validated in vivo syngeneic cell line models, as well as primary allografts of tumors, Crown helps scientists evaluate and understand novel anticancer compounds.
“In addition, we provide the unique capability to combine image-guided micro-irradiation with our syngeneic models to explore combination therapeutic strategies involving targeted irradiation with immunotherapies,” Wery added.